論文紹介：アルブミン尿の費用対効果QLAYとICER
長澤将
00:00 | 00:00
QALY（Quality-adjusted life years=質調整生存年）
ICER（Incremental cost-effectiveness ratio=増分費用効果比）
Asahi K, Konta T, Tamura K, Tanaka F, Fukui A, Nakamura Y, Hirose J, Ohara K, Shijoh Y, Carter M, Meredith K, Harris J, Åkerborg Ö, Kashihara N, Yokoo T. The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes. J Diabetes Investig. 2025 Jan;16(1):108-119. doi: 10.1111/jdi.14293. Epub 2024 Nov 22. PMID: 39576736; PMCID: PMC11693570.
Konta T, Asahi K, Tamura K, Tanaka F, Fukui A, Nakamura Y, Hirose J, Ohara K, Shijoh Y, Carter M, Meredith K, Harris J, Åkerborg Ö, Kashihara N, Yokoo T. The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients. Clin Exp Nephrol. 2024 Dec 16. doi: 10.1007/s10157-024-02600-9. Epub ahead of print. PMID: 39676148.
ICER（Incremental cost-effectiveness ratio=増分費用効果比）
Asahi K, Konta T, Tamura K, Tanaka F, Fukui A, Nakamura Y, Hirose J, Ohara K, Shijoh Y, Carter M, Meredith K, Harris J, Åkerborg Ö, Kashihara N, Yokoo T. The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes. J Diabetes Investig. 2025 Jan;16(1):108-119. doi: 10.1111/jdi.14293. Epub 2024 Nov 22. PMID: 39576736; PMCID: PMC11693570.
Konta T, Asahi K, Tamura K, Tanaka F, Fukui A, Nakamura Y, Hirose J, Ohara K, Shijoh Y, Carter M, Meredith K, Harris J, Åkerborg Ö, Kashihara N, Yokoo T. The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients. Clin Exp Nephrol. 2024 Dec 16. doi: 10.1007/s10157-024-02600-9. Epub ahead of print. PMID: 39676148.